Udemy - COVID-19 - CRISPR based diagnosis and Antibody Therapies torrent

COVID-19: CRISPR based diagnosis and Antibody Therapies
https://FreeCourseWeb.com

MP4 | Video: h264, 1280x720 | Audio: AAC, 44.1 KHz
Language: English | Size: 732 MB | Duration: 1h 56m
Learn about the CRISPR-Cas based diagnostic tests & Antibody Therapies for COVID19 | Biotechnology | Genetics | Biology
What you'll learn
What is the CRISPR-Cas system?
Cas12 and Cas13 enzymes for diagnosing infectious diseases
SHERLOCK CRISPR-Cas13-based diagnostic test kit
Recombinase Polymerase Amplification (RPA)
Detecting test results on paper strip (Lateral Flow Assay)
DETECTOR: CRISPR-Cas12-based COVID-19 Test kit
Loop Mediated Isothermal Amplification (LAMP)
FELUDA: CRISPR-Cas9-based diagnostic test
What is Convalescent Plasma therapy?
How is plasma therapy done?
Advantages and Limitations of Plasma Therapy
Monoclonal antibodies & COVID-19
Types of monoclonal antibodies to be obtained from recovered patients
How monoclonal antibodies can be isolated from COVID-19 recovered patients?
Generation of Human monoclonal antibodies against SARS-CoV-2
How are antibody therapies different from vaccination?

Requirements
Knowledge of basic biology
Motivation to learn
Description
Welcome to the Course “CRISPR-based diagnosis & Antibody therapies for COVID-19 Disease”. Since its discovery as a part of a bacterial defense mechanism, the CRISPR-Cas system has revolutionized the fields of genome editing and genetic engineering. Recently scientists all over the globe are trying to leverage the power of CRISPR to develop kits for rapid COVID-19 diagnosis.

So what is the CRISPR-Cas system and how it can be used for COVID-19 diagnosis - all of this will be discussed in detail in this course. Additionally, you will get a detailed understanding of CRISPR-based rapid and point-of-care diagnostic kits like Sherlock, DETECTR, FELUDA, etc.

In this course, We will also talk about isothermal nucleic acid amplification processes like RPA and LAMP that make them excellent candidates for developing low-cost, rapid, and point-of-care diagnosis.